[Determination of P53 in infiltrative primary bladder tumors as a prognostic factor for understaging].
OBJECTIVE
To determine if p53 expression in patients with infiltrative bladder cancer is a prognostic factor on clinical staging and cancer specific survival.


METHODS
Immunohistochemical analysis of p53 in 34 patients (33 males and 1 female) undergoing radical cystectomy for infiltrative bladder cancer, with a mean follow-up of 16 months.


RESULTS
p53 overexpression was detected in 18 patients (64%). In the p53 positive group two patients were stage T1G3, 18 patients T2, 1 patient T3, and 2 patients T4. In the negative group a better correspondence between TUR and cystectomy stage was found, with stage worsening only in 3 patients. On follow-up, p53 positive patients showed worse outcomes due to their worse stages, although no statistical differences were found (p = 0.24). In the group of patients following a bladder sparing protocol (n = 6), p53 negative patients had complete remission of the disease.


CONCLUSIONS
We see significant differences on understaging/more aggressive local outcome in p53 positive patients, with no greater mortality in this group. P53 expression does not contraindicate the inclusion of a patient in a bladder sparing protocol, although larger studies would be necessary to confirm these results.
Musquera Felip
Mireia
M
Unidad de Urología Oncológica, Servicio de Anatomía Patológica, Fundació Puigvert, Universidad Autónoma de Barcelona, España,
Palou Redorta
Juan
J
Moscatiello
Pietro
P
Huguet Pérez
Jorge
J
Rodríguez Faba
Oscar
O
Ribal Caparrós
Maria José
MJ
Algaba Arrea
Ferrán
F
Villavicencio Mavrich
Humberto
H
D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*; D001749:Urinary Bladder Neoplasms / Q000737:chemistry* / Q000473:pathology / Q000628:therapy
D016159:Tumor Suppressor Protein p53